A genetically modified mouse is provided, wherein the mouse is incapable of rearranging
and expressing an endogenous mouse immunoglobulin light chain variable sequence …

The present invention provides pharmaceutical formulations comprising a human antibody
that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may …

Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy
chain immunoglobulin locus, a humanized light chain locus that expresses a universal light …

The present invention provides methods for treating or preventing asthma and associated
conditions in a patient. The methods of the present invention comprise administering to a …

The invention discloses methods for the generation of chimaeric human-non-human
antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and …

The present invention provides nucleic acid molecules that encode antibodies or antigen-
binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also …

The present invention provides methods for treating, preventing or reducing the severity of
allergic reactions. The present invention also provides methods for enhancing the efficacy …

The invention discloses methods for the generation of chimaeric human-non-human
antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and …

The present invention relates to antagonistantibodies or frag ments thereof that bind to
human OX40. More specifically, the present invention relates to an antagonist antibody or …

2013-07-29 Assigned to REGENERON PHARMACEUTICALS, INC. reassignment
REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …